Please assess the completion status of the following clinical trial:

Trial Title: Single-dose of Nalmefene to Modulate Neural Alcohol Cue Reactivity

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: TRIPLE
- Phase: EARLY_PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* severe alcohol use disorder according to DSM 5 and heavy drinking: alcohol consumption \>=60g (men) and \>=40g (women) (minimum of 5 days / week)~* right-handedness~* normal or corrected to normal vision~* signed written informed consent~Exclusion Criteria:~valid at the time of MRI investigation:~* psychotropic medication within the last 14 days~* severe withdrawal symptoms (CIWA-Ar \> 4; Sullivan et al. 1989)~* intoxication (breath alcohol concentration \> 0.3 ‰)~* common exclusion criteria for MRI (e.g. metal, claustrophobia)~* positive drug screening (opioids, cannabinoids, benzodiazepines, barbiturates, cocaine, amphetamines)~* pregnancy~* contraindications to the prescription of nalmefene valid at inclusion:~* previous severe withdrawal / withdrawal complications~* previous inpatient detoxification treatment~* other Axis I psychiatric diagnoses than alcohol- or nicotine-dependence in the last 12 months~* neurological disorders, history of brain injury

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Nalmefene Challenge (Type: EXPERIMENTAL): Participants will receive 18mg Nalmefene two hours prior to fMRI measurement. During fMRI scanning alcohol cues will be presented.
- Placebo (Type: PLACEBO_COMPARATOR): Participants will receive Placebo two hours prior to fMRI measurement. During fMRI scanning alcohol cues will be presented.

Based on this trial design, predict the completion outcome and termination type (if applicable).